

BRAWN BIOTECH LIMITED
(Formerly Known as Brawn Pharmaceuticals Limited)
Regd Office: C-64, Lajpat Nagar-1, New Delhi 110024

Tel No. 011-32911528,529 Fax: 011-23275208; Email: solution@brawnbiotech.com; website: www.brawnbiotech.com

CIN:L74899DL1985PLC022468

Statement of Standlone Unaudited Financial Results for the quarter ended 30th June, 2015

PART I					
	Particulars	3 months ended 30/06/2015	Preceding 3 months ended 31/03/2015	Corresponding 3 months ended 30/06/2014 in the previous year	Previous year ended 31/03/2015
		Unaudited	Unaudited	Unaudited	Audited
1	Income from operations				
	Net sales/ income from operations (Net of excise duty)	958.10	776.51	747.15	3,798.08
	Other operating Income	16.67	18.30	12.02	66.56
	Total income from operations (net)	974.77	794.81	759.17	3,864.64
2	Expenses				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	812.71	686.78	620.13	3,332.58
	(c) Changes in inventories of finished goods, work-in-progress and stock-in- trade	19.84	1.15	40.58	68.31
	(d) Employee benefits expense	34.20	44.42	34.90	151.82
	(e) Depreciation and amortisation expenses	0.89	0.25	0.76	2.62
	(f) Other expenses	56.22	39.30	52.88	256.20
	Total expenses	923.85	771.91	749.25	3,811.54
3	Profit / (Loss) from operation before other income, finance costs and exceptional items (1-2)	50.92	22.91	9.92	53.11
4	Other income	0.39	3.60	0.29	5.18
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3±4)	51.31	26.50	10.21	58.28
6	Finance Cost	0.19	9.63	0.29	10.45
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5±6)	51.12	16.88	9.92	47.84
8	Exceptional items	-	-	-	-
9	Profit / (Loss) from ordinary activities before tax (7±8)	51.12	16.88	9.92	47.84
10	Tax expense	-	-	3.07	19.41
11	Net Profit / (Loss) from ordinary activities after tax (9 ± 10)	51.12	16.88	6.85	28.43
12	Extraordinary items (net of tax expense)	-	-	-	-
13	Net Profit / (Loss) for the period (11±12)	51.12	16.88	6.85	28.43
14	Paid-up equity share capital (Face Value of the Share shall be indicated)	300.03	300.03	300.03	300.03
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	244.83	193.71	172.56	193.71
16 i	Earnings per share (before extraordinary items) (not annualised): in Rs.				
	(a) Basic	0.82	0.27	0.23	0.99
	(b) Diluted	0.82	0.27	0.23	0.99
16 ii	Earnings per share (after extraordinary items) (not annualised): in Rs.				0.99
	(a) Basic	0.82	0.27	0.23	
	(b) Diluted	0.82	0.27	0.23	0.99

PART II					
Information for the quarter ended 30th June, 2015					
	Particulars	3 months ended 30/06/2015	Preceding 3 months ended 31/03/2015	Corresponding 3 months ended 30/06/2014 in the previous year	Previous year ended 31/03/2015
A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	- Number of shares	1,557,140	1,564,224	1,564,224	1,564,224
	- Percentage of shareholding	51.90	52.14	52.14	52.14
2	Promoters and Promoter group shareholding				
	a) Pledged / Encumbered				
	- Number of shares	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil
	b) Non - encumbered				
	- Number of shares	1,443,160	1,436,076	1,436,076	1,436,076
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shares (as a % of the total share capital of the company)	48.10	47.86	47.86	47.86
	Particulars				3 months ended 30/06/2015
B	INVESTOR COMPLAINTS				
	Pending at the beginning of the quarter				Nil
	Received during the quarter				Nil
	Disposed of during the quarter				Nil
	Remaining unresolved at the end of the quarter				Nil

Notes:

- 1 The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors in their Meeting held on 13.08.2015
- 2 The Statutory Auditors have carried out a Limited Review of the Financial Results for the Quarter ended 30th June, 2015
- 3 The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Accounting Standard-17 dealing with Segment Reporting.
- 4 Figures of the previous periods have been re-grouped, wherever necessary, to conform to the current periods classification
- 5 An amount of Rs. 2,68,16,475/-, appearing under Non Current Assets of the Balance Sheet for the year ended 31.03.2015, is under long pending litigation and as per views of the Board of Directors a provision for Bad and Doubtful Debts can be considered for such amount in the current Financial Year.

Dated: 13.08.2015
Place: New Delhi

For and on behalf of the Board
Sd/-
Brij Raj Gupta